As­traZeneca cuts PhI­II ALS study af­ter Alex­ion's Ul­tomiris shows 'lack of ef­fi­ca­cy'

Alex­ion has con­ced­ed its first de­feat since of­fi­cial­ly be­com­ing a sub­sidiary of As­traZeneca.

Fol­low­ing an in­ter­im analy­sis, the rare dis­ease-fo­cused group says it will scrap …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER